Theravance Biopharma, Inc. Income (Loss) from Continuing Operations, Per Basic Share
Theravance Biopharma, Inc. (TBPH) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.17 per share for the 3-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2024-03-01
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2023-12-31 was -$0.17.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2023-09-30 was -$0.17.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2023-06-30 was -$0.28.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2023-03-31 was -$0.35.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for fiscal 2023 was -$1.00.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for fiscal 2022 was -$1.26.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for fiscal 2021 was -$3.82.
- Theravance Biopharma, Inc. income (loss) from continuing operations, per basic share for fiscal 2020 was -$4.73.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$0.17 10-K · filed 2024-03-01 | -$1.00 10-K · filed 2024-03-01 | ||
| 2023-09-30 | -$0.17 10-K · filed 2024-03-01 | -$0.81 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | -$0.28 10-K · filed 2024-03-01 | -$0.63 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | -$0.35 10-K · filed 2024-03-01 | |||
| 2022-12-31 | -$0.21 10-K · filed 2024-03-01 | -$1.26 10-K · filed 2024-03-01 | ||
| 2022-09-30 | -$0.21 10-K · filed 2024-03-01 | -$1.04 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.35 10-K · filed 2024-03-01 | -$0.83 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$0.55 10-K · filed 2024-03-01 | |||
| 2021-12-31 | -$0.78 10-K · filed 2023-03-01 | -$3.82 10-K · filed 2023-03-01 | ||
| 2021-09-30 | -$0.76 10-K · filed 2023-03-01 | -$3.05 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$0.99 10-K · filed 2023-03-01 | |||
| 2021-03-31 | -$1.35 10-K · filed 2023-03-01 | |||
| 2020-12-31 | -$4.73 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |